Awards | INNOCARE

2026

Orelabrutinib was selected in 2025 Top 10 Clinical Buzzwords in Lymphoma list
InnoCare, in collaboration with Tsinghua University, was approved to establish a Beijing Key Laboratory
Orelabrutinib was selected in Guangzhou Catalog of Innovative Drugs and Medical Devices
Tafasitamab was awarded the "Sunshine" Annual Outstanding Newly Approved Innovative Pharmaceutical Product
InnoCare obtained approval to set up another Beijing Key Laboratory
Dr. Jasmine Cui was named one of Forbes China's Outstanding Businesswomen for the second consecutive year
Dr. Jasmine Cui was named one of Forbes China's Best CEOs of 2026
InnoCare was selected in S&P Global's 2025 Sustainability Yearbook (China Edition)
InnoCare was listed in 2025 Top 30 Global-Competitive Chinese Innovative Pharma
InnoCare was listed 157th in 2025 Top 500 New Economy Enterprises

2025

InnoCare nominated for Beijing Municipal Government Quality Management Award
InnoCare was listed in the Top 100 Beijing Private Enterprises in Technological Innovation
InnoCare received the highest A-rating for information disclosure from the Shanghai Stock Exchange
InnoCare was awarded Beijing March 8th Red Banner Collective
Mesutoclax (ICP-248) was listed in Top 100 New Technologies and New Products at ZGC Forum
Dr. Jasmine Cui was listed in Forbes China 2025 Top 100 Businesswomen
Dr. Jasmine Cui won SAPA (Sino-American Pharmaceutical Professionals Association) Outstanding Achievement Award

2024

InnoCare was listed in 2024 Top 100 Beijing Private Enterprises in Technological Innovation
Orelabrutinib patent won the First Prize of Beijing Invention Patent Award
Orelabrutinib was selected as a Demonstration Case of New Quality Productive Forces Industrial Practice
Nanjing R&D Center was certified as an SRDI (Specialized, Refined, Differential and Innovative) SME (small and medium-sized enterprises)
Nanjing R&D Center was recognized as 2024 Nanjing Engineering Technology Research Center

2023

InnoCare was certified as a national specialized, refined, differential and innovative (SRDI) “little giant” enterprise
ICP-332 was listed in the Top 10 Influential New Technologies and Products in the 2023 Zhongguancun Forum
Dr. Jasmine Cui was awarded the Top 10 Drug Innovation Leaders of the Year by Securities Times
Dr. Jasmine Cui was awarded the 2023 Outstanding Leader of China’s Healthcare Industry by Forbes
Dr. Jasmine Cui won the Top 30 Influential Women in Healthcare Industry 2023 award issued by Healthcare Executive
Guangzhou InnoCare was certified as an SRDI SME
Guangzhou InnoCare was listed in Guangzhou's Top 100 Cutting-edge Enterprises

2022

InnoCare was listed in China’s Top 100 Innovative Biopharmaceutical Enterprises of 2022 by yaozh.com
InnoCare ranked fifth in the list of China’s Top 30 Innovative Small Molecule Drug Enterprises of 2022 released by Menet
InnoCare was listed in the 2022 Top 500 New Economy Enterprises of China
InnoCare was listed in the Top 15 Biotech Stocks in the Top 100 Hong Kong Listed Companies
InnoCare was listed in China’s Top 10 Innovative Pharmaceutical Enterprises of 2022 by EOHealthcare
InnoCare was awarded the Most Valuable Pharmaceutical and Healthcare Company by Zhitong Finance
InnoCare was listed in China’s Top 100 Pharmaceutical R&D Companies by yaozh.com and China Pharmaceuticals
InnoCare was honored as the Most Valuable IPO of the Year and Outstanding PR Team of the Year by Guru Club
InnoCare was listed in the Top 100 Enterprises for Overall Competitiveness in the Healthcare Industry of 2022 by CPEO
InnoCare was awarded as a Beijing Intellectual Property Model Enterprise
InnoCare was listed in China’s Top 100 Innovative Pharmaceutical Enterprises of 2022 by Healthcare Executive
InnoCare was honored as one of the Top 20 Influential Small Molecule Innovative Drug Enterprises in the 2022 China Biopharmaceutical Industry Value List
InnoCare was listed in the Top 15 Biotech Stocks in the Top 100 Hong Kong Listed Companies
InnoCare was listed in the Top 10 Innovative Enterprises in Precision Medicine of 2022 by China Times
InnoCare was awarded the NetEase Finance Golden Battle-axe Award – Company with the Best CSR Reputation of 2022
InnoCare won the title of “Best Investor Relations” granted by Hithink RoyalflushOrelabrutinib was selected as the 2022 Outstanding Business Value Case by 21st Century Business Herald
Orelabrutinib won the Gold Award in the 16th Beijing Invention and Innovation Competition
Orelabrutinib was granted the Beijing New Technology and New Products (Services) Certificate by five government authoritatities
Dr. Jasmine Cui was honored as one of the Most Powerful Women in China by Fortune
Guangzhou InnoCare was certified as a high-tech enterprise
Guangzhou InnoCare was certified as an innovative SME
Guangzhou InnoCare was certified as the Solubilization Preparation Technology R&D Center in Guangdong
Guangzhou InnoCare was certified as a technologically advanced service enterprise

2021

InnoCare was awarded the Pioneer Enterprises of Independent Innovation in China’s Pharmaceutical Industry in 2021 by All-China Federation of Industry&Commerce, Medical&Pharmaceutical Chamber
InnoCare was listed in China’s Top 30 Innovative Small Molecule Drug Enterprises of 2021 by Menet
Orelabrutinib R&D team was awarded the Top 10 Drug Innovation R&D Teams by Securities Times
InnoCare was among the 2021 Top 500 New Economy Enterprises list released by China Enterprise Evaluation Association
InnoCare was awarded the Best Content Award of 2021 Corporate Communications Award
InnoCare was awarded the Most Valuable Pharmaceutical and Healthcare Enterprises at the 6th Hong Kong Golden Stocks Awards Ceremony by Zhitong Finance
InnoCare was awarded the Listed Company with the Most Growth Potential at the Golden Kirin Hong Kong and American Stock Listed Companies Award Ceremony by Sina Finance
InnoCare was listed in China’s Top 100 Innovative Pharmaceutical Enterprises of 2021 by Healthcare Executive
InnoCare was awarded the Best Investors Relations Listed Enterprises of China Securities Golden Awards in the 11th Hong Kong IFW
InnoCare was awarded the Most Innovative Listed Enterprises of the Greater China in 2021 by Guru Club
InnoCare was listed 20 Most Valuable Biotechs in Asia by Torreya
InnoCare was honored the Kunpeng Award – 2021 Top 3 Enterprises of the Best Originally Developed Small Molecule Drugs
InnoCare ranked fifth in the list of China’s Top 30 Innovative Small Molecule Drug Enterprises of 2021 released by Menet
InnoCare was granted the Top 10 Companies in Drug Innovation of 2020 Drug Innovation Jishi Award by Securities Times
InnoCare (Nanjing) was certified as a high-tech enterprise
Orelabrutinib was awarded the Outstanding Innovative Products at the 2021 Digital Transformation and Innovation Forum by The Economic Observer
Orelabrutinib was awarded the Most Popular Innovative Drugs in 2021 by Sina Medicine
Orelabrutinib was awarded the Top 10 Excellent Innovative Anti-Cancer Drug Cases of the Year at the Healthy China 21 CC by 21st Century Business Herald
Orelabrutinib was awarded the 2020 Drug of the Year at the 2021 CPEO
Orelabrutinib was selected as one of the Sci-Tech Innovation Service Examples by the China International Fair for Trade in Services (CIFTIS) 2021
Orelabrutinib was awarded the Top 10 Drug Innovation Achievement Award in 2020
Orelabrutinib was awarded China’s Effective Pharmaceutical Products by Sailing Health
Dr. Jasmine Cui was awarded the Outstanding Innovation Leader at the 10th Finance Industry China Jinzhi Award Annual Ceremony
Dr. Jasmine Cui was awarded the BayHelix Woman Leader of the Year in 2021
Dr. Jasmine Cui was awarded the 2020 Top 10 Drug Innovation Leaders at the Drug Innovation Award Ceremony by Securities Times
Dr. Renbin Zhao was listed in Forbes Chinese Women in Tech 2021